Relypsa Inc  

(Public, NASDAQ:RLYP)   Watch this stock  
Find more results for J. Thomas Corbett
24.64
-0.22 (-0.88%)
Nov 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 24.45 - 25.15
52 week 13.00 - 52.74
Open 25.00
Vol / Avg. 0.00/250,102.00
Mkt cap 851.85M
P/E     -
Div/yield     -
EPS -1.93
Shares 34.21M
Beta     -
Inst. own 93%
Nov 19, 2014
Relypsa Inc at Stifel Healthcare Conference
Nov 10, 2014
Q3 2014 Relypsa Inc Earnings Release
Nov 6, 2014
Relypsa Inc at Nomura Biotechnology Conference
Oct 7, 2014
Relypsa Inc at BIO Investor Forum
Sep 26, 2014
Relypsa Inc at BioCentury Publications NewsMakers in the Biotech Industry
Sep 9, 2014
Relypsa Inc at Morgan Stanley Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -47.56% -86.79%
Return on average equity -58.52% -
Employees 76 -
CDP Score - -

Address

700 Saginaw Drive
REDWOOD CITY, CA 94063
United States - Map
+1-650-4219500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Relypsa, Inc. is a pharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The Company has completed its two-part pivotal Phase III trial of its product candidate, patiromer, for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood. The Company has designed patiromer to efficiently bind and remove potassium from the body, thereby treating hyperkalemia. The Company has conducted a clinical development program, in which daily administration of patiromer has been observed by the Company to lower, and maintain control of, serum potassium levels in hyperkalemic subjects with an acceptable safety and tolerability profile.

Officers and directors

Scott M. Rocklage Ph.D. Chairman of the Board
Age: 52
Bio & Compensation  - Reuters
John A. Orwin President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Kristine M. Ball Chief Financial Officer and Senior Vice President
Age: 42
Bio & Compensation  - Reuters
Ronald A. Krasnow J.D. Senior Vice President, General Counsel, Secretary
Age: 51
Bio & Compensation  - Reuters
Mary Corbett Senior Vice President - Human Resources
Age: 62
Bio & Compensation  - Reuters
Lance Berman M.D. Chief Medical Officer and Senior Vice President
Age: 43
Bio & Compensation  - Reuters
J. Scott Garland Senior Vice President, Chief Commercial Officer
Age: 45
Bio & Compensation  - Reuters
Claire J. Lockey Senior Vice President - Pharmaceutical Development and Regulatory Affairs
Age: 61
Bio & Compensation  - Reuters
Wilhelm Stahl Ph.D. Senior Vice President - Pharmaceutical Operations
Age: 54
Bio & Compensation  - Reuters
David W. J. McGirr Director
Age: 60
Bio & Compensation  - Reuters